NI201400031A - Derivados de ( 4 - fenilimidazol - 2 - il ) etilamina útiles como moduladores de canal de sodio - Google Patents

Derivados de ( 4 - fenilimidazol - 2 - il ) etilamina útiles como moduladores de canal de sodio

Info

Publication number
NI201400031A
NI201400031A NI201400031A NI201400031A NI201400031A NI 201400031 A NI201400031 A NI 201400031A NI 201400031 A NI201400031 A NI 201400031A NI 201400031 A NI201400031 A NI 201400031A NI 201400031 A NI201400031 A NI 201400031A
Authority
NI
Nicaragua
Prior art keywords
phenylimidazole
sodium channel
derivatives useful
channel modulators
ethylamine derivatives
Prior art date
Application number
NI201400031A
Other languages
English (en)
Inventor
Kaur Bagal Sharanjeet
Ian Kemp Mark
Charles Miller Duncan
Murata Yoshihisa
Original Assignee
Pfizer Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47278356&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NI201400031(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Ltd filed Critical Pfizer Ltd
Publication of NI201400031A publication Critical patent/NI201400031A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La invención se refiere a derivados imidazol, a su uso en medicina, a composiciones que los contienen, a procesos para su preparación y a intermediaros utilizados en tales procesos. Más particularmente, la invención se refiere a nuevos moduladores Nav1.8 imidazol de la formula (I): o una sal farmacéuticamente aceptable del mismo, en donde R1, R2, R3, R4 y R5 son como se definen en la descripción. Los moduladores Nav1.8 son potencialmente útiles en el tratamiento de un amplio margen de trastornos, particularmente dolor.
NI201400031A 2011-10-26 2014-04-23 Derivados de ( 4 - fenilimidazol - 2 - il ) etilamina útiles como moduladores de canal de sodio NI201400031A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161551628P 2011-10-26 2011-10-26

Publications (1)

Publication Number Publication Date
NI201400031A true NI201400031A (es) 2014-10-01

Family

ID=47278356

Family Applications (1)

Application Number Title Priority Date Filing Date
NI201400031A NI201400031A (es) 2011-10-26 2014-04-23 Derivados de ( 4 - fenilimidazol - 2 - il ) etilamina útiles como moduladores de canal de sodio

Country Status (28)

Country Link
US (1) US9079878B2 (es)
EP (1) EP2771335A2 (es)
JP (1) JP5946538B2 (es)
KR (1) KR101586966B1 (es)
CN (1) CN103906746B (es)
AP (1) AP2014007579A0 (es)
AU (1) AU2012328034B2 (es)
BR (1) BR112014009102A2 (es)
CA (1) CA2850925C (es)
CL (1) CL2014000956A1 (es)
CO (1) CO6940427A2 (es)
CR (1) CR20140185A (es)
CU (1) CU20140046A7 (es)
DO (1) DOP2014000085A (es)
EA (1) EA023375B1 (es)
EC (1) ECSP14013324A (es)
GT (1) GT201400079A (es)
HK (1) HK1198650A1 (es)
IL (1) IL232267A (es)
MD (1) MD20140037A2 (es)
MX (1) MX337469B (es)
NI (1) NI201400031A (es)
PE (1) PE20141682A1 (es)
SG (1) SG11201401032YA (es)
TN (1) TN2014000147A1 (es)
UA (1) UA109220C2 (es)
WO (1) WO2013061205A2 (es)
ZA (1) ZA201402281B (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2014003064A (es) * 2011-09-14 2014-05-07 Dow Agrosciences Llc Metodos y sistemas para formar acidos boronicos y sus intermedios.
CA2931550C (en) 2013-12-13 2023-09-26 Vertex Pharmaceuticals Incorporated Prodrugs of pyridone amides useful as modulators of sodium channels
KR102192572B1 (ko) 2014-06-09 2020-12-18 삼성전자주식회사 광원 모듈의 불량 검사방법, 광원 모듈의 제조 방법 및 광원 모듈 검사장치
WO2016065341A1 (en) 2014-10-24 2016-04-28 Avectas Limited Delivery across cell plasma membranes
BR112017017619A2 (pt) 2015-02-19 2018-05-08 Purdue Pharma Lp métodos e composições para diminuir esvaziamento gástrico
IS2977B (is) 2015-02-23 2017-07-15 Actavis Group Ptc Ehf. Aðferð til framleiðslu á milliefnum sem eru nytsamleg við nýsmíði á elúxadólíni
AU2016380836A1 (en) 2015-12-30 2018-07-12 Avectas Limited Vector-free delivery of gene editing proteins and compositions to cells and tissues
AU2017292169B2 (en) * 2016-07-06 2021-12-23 Vertex Pharmaceuticals Incorporated Materials and methods for treatment of pain related disorders
US11459587B2 (en) 2016-07-06 2022-10-04 Vertex Pharmaceuticals Incorporated Materials and methods for treatment of pain related disorders
IL270680B (en) 2017-05-16 2022-06-01 Vertex Pharma Deuterium-converted pyridone amides and their prodrugs as sodium channel modulators
TW201920081A (zh) 2017-07-11 2019-06-01 美商維泰克斯製藥公司 作為鈉通道調節劑的羧醯胺
TW202002971A (zh) 2018-02-12 2020-01-16 美商維泰克斯製藥公司 治療疼痛的方法
WO2020146682A1 (en) 2019-01-10 2020-07-16 Vertex Pharmaceuticals Incorporated Carboxamides as modulators of sodium channels
US20220110923A1 (en) 2019-01-10 2022-04-14 Vertex Pharmaceuticals Incorporated Esters and carbamates as modulators of sodium channels
WO2020176763A1 (en) 2019-02-27 2020-09-03 Vertex Pharmaceuticals Incorporated Dosage form comprising prodrug of na 1.8 sodium channel inhibitor
WO2020219867A1 (en) 2019-04-25 2020-10-29 Vertex Pharmaceuticals Incorporated Pyridone amide co-crystal compositions for the treatment of pain
JOP20220130A1 (ar) 2019-12-06 2023-01-30 Vertex Pharma مجموعات تترا هيدروفيوران بها استبدال في صورة عوامل تعديل لقنوات الصوديوم
WO2022256702A1 (en) 2021-06-04 2022-12-08 Vertex Pharmaceuticals Incorporated Substituted tetrahydrofuran-2-carboxamides as modulators of sodium channels
UY39800A (es) 2021-06-04 2023-01-31 Vertex Pharma N–(hidroxialquil (hetero)aril) tetrahidrofuran carboxamidas como moduladores de canales de sodio
EP4346818A1 (en) 2021-06-04 2024-04-10 Vertex Pharmaceuticals Incorporated Solid dosage forms and dosing regimens comprising (2r,3s,4s,5r)-4-[[3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl) tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide
WO2022256842A1 (en) 2021-06-04 2022-12-08 Vertex Pharmaceuticals Incorporated Hydroxy and (halo)alkoxy substituted tetrahydrofurans as modulators of sodium channels
CN117794918A (zh) 2021-06-04 2024-03-29 沃泰克斯药物股份有限公司 经取代的四氢呋喃类似物作为钠通道调节剂
CA3221939A1 (en) 2021-06-04 2022-12-08 Vertex Pharmaceuticals Incorporated N-(hydroxyalkyl (hetero)aryl) tetrahydrofuran carboxamide analogs as modulators of sodium channels
US20230382910A1 (en) 2022-04-22 2023-11-30 Vertex Pharmaceuticals Incorporated Heteroaryl compounds for the treatment of pain
WO2023205465A1 (en) 2022-04-22 2023-10-26 Vertex Pharmaceuticals Incorporated Heteroaryl compounds for the treatment of pain
WO2023205468A1 (en) 2022-04-22 2023-10-26 Vertex Pharmaceuticals Incorporated Heteroaryl compounds for the treatment of pain
TW202404969A (zh) 2022-04-22 2024-02-01 美商維泰克斯製藥公司 用於治療疼痛之雜芳基化合物
WO2023211990A1 (en) 2022-04-25 2023-11-02 Siteone Therapeutics, Inc. Bicyclic heterocyclic amide inhibitors of na v1.8 for the treatment of pain

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
GB9518953D0 (en) 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
WO2000035298A1 (en) 1996-11-27 2000-06-22 Wm. Wrigley Jr. Company Chewing gum containing medicament active agents
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
TWI283577B (en) * 1999-10-11 2007-07-11 Sod Conseils Rech Applic Pharmaceutical composition of imidazole derivatives acting as modulators of sodium channels and the use thereof
US7291641B2 (en) * 1999-10-11 2007-11-06 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) Derivatives of heterocycles with 5 members, their preparation and their use as medicaments
US7112366B2 (en) 2001-01-05 2006-09-26 The Ohio State University Chemical monolayer and micro-electronic junctions and devices containing same
TWI248438B (en) * 2001-04-10 2006-02-01 Sod Conseils Rech Applic Derivatives of heterocycles with 5 members, their preparation and their use as medicaments
FR2842808B1 (fr) 2002-07-25 2004-09-10 Sod Conseils Rech Applic Nouveaux derives d'arylimidazoles, leur preparation et leurs applications therapeutiques
CN1950351B (zh) * 2004-05-07 2012-01-18 沃尼尔·朗伯有限责任公司 适用作h3配体的3-或4-单取代酚及苯硫酚衍生物
US7456164B2 (en) * 2004-05-07 2008-11-25 Pfizer, Inc 3- or 4-monosubtituted phenol and thiophenol derivatives useful as H3 ligands
EP2371954A1 (en) * 2004-10-27 2011-10-05 Schering Corporation Compositions and methods for short interfering nucleic acid inhibition of NAv1.8
PT1963280E (pt) 2005-12-22 2016-02-02 Newron Pharm Spa Derivados de 2-feniletilamino como cálcio e/ou moduladores do canal de sódio
ES2357340T3 (es) 2006-10-18 2011-04-25 Pfizer Products Inc. Compuestos de biaril éter urea.
CL2008000835A1 (es) 2007-03-23 2008-10-03 Icagen Inc Pfizer Ltd Compuestos derivados de sulfonamidas, inhibidores de los canales de calcio; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del dolor, sindrome de intestino irritable, enfermedad de crohn, taquiarritm
CA2685952C (en) * 2007-05-03 2012-03-13 Pfizer Limited N- [6-amino-5- (phenyl) pyrazin-2-yl] -isoxazole-4-carboxamide derivatives and related compounds as nav1.8 channel modulators for the treatment of pain
WO2008135826A2 (en) 2007-05-03 2008-11-13 Pfizer Limited 2 -pyridine carboxamide derivatives as sodium channel modulators
US8124610B2 (en) 2007-07-13 2012-02-28 Icagen Inc. Sodium channel inhibitors

Also Published As

Publication number Publication date
CA2850925A1 (en) 2013-05-02
GT201400079A (es) 2015-06-02
BR112014009102A2 (pt) 2017-04-18
EA023375B1 (ru) 2016-05-31
CN103906746A (zh) 2014-07-02
CL2014000956A1 (es) 2014-07-18
AU2012328034A1 (en) 2014-05-15
ECSP14013324A (es) 2014-05-31
WO2013061205A8 (en) 2014-03-27
TN2014000147A1 (fr) 2015-09-30
US9079878B2 (en) 2015-07-14
CN103906746B (zh) 2015-12-09
CU20140046A7 (es) 2014-10-02
MX337469B (es) 2016-03-02
EP2771335A2 (en) 2014-09-03
MD20140037A2 (ro) 2014-08-31
CA2850925C (en) 2017-01-10
IL232267A0 (en) 2014-06-30
UA109220C2 (uk) 2015-07-27
IL232267A (en) 2016-10-31
KR20140069234A (ko) 2014-06-09
KR101586966B1 (ko) 2016-01-19
NZ623090A (en) 2015-10-30
WO2013061205A2 (en) 2013-05-02
MX2014004738A (es) 2014-08-01
HK1198650A1 (en) 2015-05-22
PE20141682A1 (es) 2014-11-14
SG11201401032YA (en) 2014-07-30
ZA201402281B (en) 2015-11-25
EA201490864A1 (ru) 2014-08-29
AP2014007579A0 (en) 2014-04-30
AU2012328034B2 (en) 2015-04-23
JP2014530900A (ja) 2014-11-20
JP5946538B2 (ja) 2016-07-06
CO6940427A2 (es) 2014-05-09
CR20140185A (es) 2014-06-03
DOP2014000085A (es) 2014-08-31
WO2013061205A3 (en) 2013-06-27
US20140296313A1 (en) 2014-10-02

Similar Documents

Publication Publication Date Title
NI201400031A (es) Derivados de ( 4 - fenilimidazol - 2 - il ) etilamina útiles como moduladores de canal de sodio
NI202000078A (es) Compuestos heteroaril tetracíclicos
CO2022004594A2 (es) Oxinitruro de piridina, método para su preparación y uso de este
UY33500A (es) Derivados de acil sulfonamida y sus sales farmacéuticamente aceptables para uso en medicina
UY33501A (es) Derivados de acil sulfonamida y sus sales farmacéuticamente aceptables para uso en medicina
UY33491A (es) ?Derivados de sulfonamida y sus sales farmacéuticamente aceptables para uso en medicina?.
UY32156A (es) Derivados sustituidos de la n2 - [1-(5 - fluoropirimidin -2-il) etil] - n4 - (1-metil - 1h-imidazol - 4 - il)) - pirimidina - 2,4 - diaminas y sus sales farmacéuticamente aceptables, proceso de preparación, composiciones conteniéndolos y aplicaciones.
CU20160063A7 (es) Derivados de pirazol fusionados activos como moduladores del receptor de farnesoide x
CU20170144A7 (es) Compuestos de tetrahidroquinolinona sustituidos como moduladores gamma ror
DOP2014000008A (es) 4-imidazopiridazina-1-il-benzamidas y 4-imidazotriazina-1-il-benzamidas como inhibidores de btk
CO6690768A2 (es) Derivados de triazina-oxadiazoles, útiles como inhibidores de los canales de sodio navi.7
PE20151438A1 (es) Moduladores de receptores nmda de espiro-lactama y sus usos
PE20151436A1 (es) Moduladores de receptores nmda de espiro-lactama y sus usos
PE20151427A1 (es) Moduladores de receptores nmda de espiro-lactama y sus usos
EA201600337A1 (ru) 2,6-замещенные пуриновые производные и их применение в лечении пролиферативных заболеваний
EA201992679A1 (ru) N-замещенные индольные производные
EA201990388A1 (ru) Пиперидиновые модуляторы рецепторов cxcr7
EA201501163A1 (ru) Модуляторы рецептора cxcr7
ECSP21037191A (es) Pirazoles como moduladores de la hemoglobina
CL2017002498A1 (es) Piridopirimidinonas y su uso como modulares del receptor nmda
EA202092955A1 (ru) Алкоксизамещенные пиридинильные производные в качестве антагонистов рецепторов lpa1 и их применение для лечения фиброза
UY33745A (es) Derivados de difenilamina: usos, procedimiento de síntesis y composiciones farmacéuticas
ES2418032R1 (es) Derivados de 2-(1-fenil-4,5,6,7-tetrahidro-1h-indazol-4-il)etilamina utiles como inhibidores de receptores sigma
EA202092600A1 (ru) Тетрациклические гетероарильные соединения
EA201991734A1 (ru) Модуляторы рецептора эстрогена